Torrent Pharma at 58x PE – Strong Dose or Overprescribed?
1. 🧠 At a Glance
Torrent Pharma is the Torrent Group’s most profitable unit — manufacturing branded generics in India, Brazil, and Germany. It boasts top-tier margins and 27% ROCE. But here’s the warning label: sales growth is just 8% CAGR, valuation is spicy at 58x P/E, and debt’s still there. The business is solid, but the stock… is it overdosing?
2. 🎬 Introduction with Hook
There are two kinds of medicines — those that heal and those that cost your kidney. Torrent Pharma, at ₹3,314 per share and a 58.6x P/E, sits somewhere in between.
It’s got: 💊 Branded generics that sell like hotcakes in India and Brazil 📈 Margins that rival premium MNCs 📉 But growth that’s — dare we say — a little pain relief spray level weak
3. 🏭 Business Model (WTF Do They Even Do?)
Torrent focuses on branded generics — where you slap a brand name on an off-patent molecule and sell it like luxury toothpaste.
